Nicopass Reglisse Menthe Sans Sucre, Édulcorée À L'aspartam Et À L'acésulfame Potassique (Nicotine Resinate)

Nicotine resinate is used within nicotine replacement therapy to address tobacco‑related dependence.

• Smoking cessation: assists adults in quitting cigarettes by providing a controlled nicotine dose.
• Nicotine dependence: helps manage cravings and withdrawal during the quitting process.
• Tobacco use disorder: reduces the urge to smoke and supports gradual reduction of nicotine intake.

• Nicotine resinate acts as a partial agonist at neuronal nicotinic acetylcholine receptors, especially the α4β2 subtype. By binding to these receptors, it delivers a modest nicotine stimulus that alleviates withdrawal while preventing the full activation that occurs with cigarette smoking, thereby reducing cravings and the reinforcing effects of tobacco.

Adverse reactions may occur with any nicotine replacement product.

Common Side Effects

• Mouth irritation or soreness
• Nausea or upset stomach
• Hiccups or throat discomfort
• Altered taste sensation
• Increased salivation
• Headache

Serious or Rare Side Effects

• Allergic reaction (rash, swelling, difficulty breathing)
• Severe mouth ulceration or ulcerative lesions
• Cardiovascular events (palpitations, hypertension)
• Hypotension or fainting
• Seizures (rare)
• Persistent vomiting or severe gastrointestinal distress

Before using Nicopass Reglisse Menthe Sans Sucre, consider the following safety measures.

• Pregnancy: safety not established; consult a healthcare professional before use.
• Breastfeeding: unknown effects; avoid unless advised by a clinician.
• Cardiovascular disease: use with caution, monitor blood pressure and heart rate.
• Concurrent nicotine products: avoid simultaneous use to prevent nicotine overdose.
• Storage: Store below 25°C: keep in the original pack, protect from moisture.

Nicotine resinate may interact with other medicines; review the following categories.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors: increased risk of hypertensive crisis.
• CYP2A6 inhibitors (e.g., methoxsalen): may raise nicotine plasma levels.
• Other nicotine replacement products: risk of nicotine toxicity.
• Bupropion or other seizure‑threshold‑lowering agents: heightened seizure risk.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: nicotine may diminish their effectiveness.
• Insulin or oral hypoglycemics: nicotine can affect glucose control.
• Theophylline: nicotine may accelerate its metabolism, reducing therapeutic effect.